Amgen Issues Credit to 340B Covered Entities Due to Miscalculation of Drug Ceiling Price

AAFCPAs would like to make clients aware of potential credits owed to your organization as a result of a miscalculation of a drug ceiling price.  Recently, the drug manufacturer Amgen USA Inc. notified the Health Resources and Services Administration (HRSA) that the 340B ceiling price for multiple products had been calculated incorrectly and that credits may be owed to affected covered entities.
Amgen stated that the ceiling price was improperly calculated from October 2006 through March 2015 on products using NDC labeler codes 55513 and 58406. This includes: Aranesp®, Enbrel®, Epogen®, Neulasta®, Neupogen®, Vectibix®, Nplate®, Prolia®, and Sensipar®.  Affected covered entities should receive a credit within the next three to four months based upon activity with the manufacturer, accompanied by a letter detailing the change in price.
AAFCPAs encourages healthcare clients participating in the 340B drug pricing program to click here to review the full listing of affected National Drug Codes (NDCs). >>   If you feel that you were overcharged for the purchase of a 340B covered outpatient drug, you may contact Amgen directly at 340BRelations@amgen.com.
AAFCPAs delivers a full range of solutions solving the challenges that AAF’s healthcare clients face, including: guidance on compliance with 340B pharmacy program requirements, and program audits of both on-site and contract pharmacies.  If you have any questions or need additional information, please contact your AAF Partner, or Courtney McFarland, CPA: 774.512.4051, cmcfarland@aafcpa.com.